Last update 26 Dec 2024

Carotuximab

Last update 26 Dec 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Carotuximab (USAN/INN), Chimeric anti-CD105 antibody, Chimeric Antibody TRC-105

+ [6]

Target

ENG

Mechanism

ENG inhibitors(endoglin inhibitors), Angiogenesis inhibitors

Therapeutic Areas

NeoplasmsUrogenital DiseasesSkin and Musculoskeletal Diseases+ [1]

Active Indication

Metastatic castration-resistant prostate cancerHormone receptor positive HER2 negative breast cancerLocally advanced breast cancer+ [3]

Inactive Indication

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaBladder Cancer+ [24]

Originator Organization

Roswell Park Comprehensive Cancer Center

TRACON Pharmaceuticals, Inc.

Active Organization

Cedars-Sinai Medical Center

TRACON Pharmaceuticals, Inc.

Kairos Pharma Ltd.Startup

+ [1]

Inactive Organization

Ambrx, Inc.

Santen Pharmaceutical Co., Ltd.

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Gene Sequence

Sequence Code 319922187H

Source: *****

Sequence Code 319922188L

Source: *****

Clinical Trials associated with Carotuximab

NCT05534646 / RecruitingPhase 2IIT

Phase II Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer

This is an open-label, multi-site study of apalutamide with carotuximab in patients who have progressed on androgen receptor signaling inhibitor (ARSI) therapy. This study will begin with a safety assessment in the first 10 subjects (part 1: Safety Lead-in). If the combination is deemed safe, the trial will proceed to the Phase II stage. The purpose of this study is to compare progression free survival (PFS) between patients receiving apalutamide and apalutamide + carotuximab using Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3. The secondary objectives are to describe adverse events related to the intervention, overall response rate (ORR), proportion of patients resistant to apalutamide that benefit from the addition of carotuximab, and to determine the ORR, radiographic PFS, and biochemical PFS in the overall population.

Start Date27 Dec 2023

Sponsor / Collaborator

Cedars-Sinai Medical Center

NCT05401110 / RecruitingPhase 1IIT

IIT2021-12-Reckamp-Osi105: Phase I Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

The purpose of this study is to examine the combination of osimertinib and carotuximab to assess the safety and find the recommended dose for treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC). Safety and tolerability will be measured by the number of dose-limiting toxicities, according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 5, to find the maximum tolerated dose. The secondary objectives include evaluating the rate of objective response rate, duration of response, progression-free survival, and disease control rate, along with assessing biomarkers through tumor tissue and circulating tumor DNA.

Start Date15 Sep 2023

Sponsor / Collaborator

Cedars-Sinai Medical Center

NCT03418324 / CompletedPhase 2IIT

A Phase 2 Study of TRC105 (Anti-endoglin Antibody) With Abiraterone and With Enzalutamide in Metastatic, Castration Resistant Prostate Cancer Patients Progressing on Therapy

This research study is being done to measure the clinical benefit of TRC105 in combination with abiraterone or enzalutamide in metastatic, castration-resistant prostate cancer patients who are taking either abiraterone or enzalutamide and showing signs of biochemical progression without radiographic progression. A patient who is progressing on AR-therapy will continue the same AR-therapy on study with the addition of TRC105. The two arms will accrue in parallel and independently.

Start Date05 Mar 2018

Sponsor / Collaborator

Cedars-Sinai Medical Center

100 Clinical Results associated with Carotuximab

100 Translational Medicine associated with Carotuximab

100 Patents (Medical) associated with Carotuximab

Literatures (Medical) associated with Carotuximab

01 Apr 2023·Breast cancer research and treatment

A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer

Article

Author: Acosta, Edward P ; Vaklavas, Christos ; Wei, Shi ; Grizzle, William E ; Stringer-Reasor, Erica M ; Forero-Torres, Andres ; Elkhanany, Ahmed M ; Li, Yufeng ; Ryan, Kevin J ; Theuer, Charles P ; Yang, Eddy S

Abstract:

Purpose:

In nonmetastatic hormone receptor-positive and Her2-negative breast cancer, preoperative endocrine therapies can yield outcomes similar with chemotherapy. We evaluated the tolerability and preliminary antitumor activity of preoperative letrozole, everolimus, and carotuximab, a monoclonal antibody targeting endoglin, in nonmetastatic breast cancer.

Methods:

Eligible patients had newly diagnosed, stage 2 or 3, hormone receptor-positive and Her2/neu-negative breast cancer. Patients received escalating doses of everolimus; the dose of letrozole and carotuximab were fixed at 2.5 mg PO daily and 15 mg/kg intravenously every 2 weeks, respectively. The primary objective was to determine the safety and tolerability of the combination. Secondary objectives included pharmacokinetic and pharmacodynamic studies and assessments of antitumor activity.

Results:

Fifteen patients enrolled. The recommended phase 2 dose of everolimus in combination with letrozole and carotuximab was 10 mg PO daily. The most frequent adverse events were headache (67%), fatigue (47%), facial flushing and swelling (47%), gingival hemorrhage (40%), epistaxis (33%), nausea and vomiting (27%). Headache constituted a dose-limiting toxicity. At least two signs of mucocutaneous telangiectasia developed in 92% of patients. Carotuximab accumulated in the extravascular space and accelerated the biodistribution and clearance of everolimus. All patients had residual disease. Gene expression analyses were consistent with downregulation of genes involved in proliferation and DNA repair. Among 6 patients with luminal B breast cancer, 5 converted to luminal A after one cycle of therapy.

Conclusion:

Letrozole, everolimus, and carotuximab were tolerated in combination at their single-agent doses. Pharmacokinetic studies revealed an interaction between everolimus and carotuximab.

Trial registration:

This trial is registered with ClinicalTrials.gov (Identifier: NCT02520063), first posted on August 11, 2015, and is active, not recruiting.

01 Jan 2023·Frontiers in medicine

Endoglin and squamous cell carcinomas.

Article

Author: Boonstra, Jurjen J ; Harryvan, Tom J ; Hakuno, Sarah K ; Janson, Stefanus G T ; Dinjens, Winand N M ; de Jonge-Muller, Eveline ; de Graaf, Manon ; Hawinkels, Lukas J A C ; Slingerland, Marije ; Trietsch, Marjolijn D ; Crobach, Stijn

Despite the fact that the role of endoglin on endothelial cells has been extensively described, its expression and biological role on (epithelial) cancer cells is still debatable. Especially its function on squamous cell carcinoma (SCC) cells is largely unknown. Therefore, we investigated SCC endoglin expression and function in three types of SCCs; head and neck (HNSCC), esophageal (ESCC) and vulvar (VSCC) cancers. Endoglin expression was evaluated in tumor specimens and 14 patient-derived cell lines. Next to being expressed on angiogenic endothelial cells, endoglin is selectively expressed by individual SCC cells in tumor nests. Patient derived HNSCC, ESCC and VSCC cell lines express varying levels of endoglin with high interpatient variation. To assess the function of endoglin in signaling of TGF-β ligands, endoglin was overexpressed or knocked out or the signaling was blocked using TRC105, an endoglin neutralizing antibody. The endoglin ligand BMP-9 induced strong phosphorylation of SMAD1 independent of expression of the type-I receptor ALK1. Interestingly, we observed that endoglin overexpression leads to strongly increased soluble endoglin levels, which in turn decreases BMP-9 signaling. On the functional level, endoglin, both in a ligand dependent and independent manner, did not influence proliferation or migration of the SCC cells. In conclusion, these data show endoglin expression on individual cells in the tumor nests in SCCs and a role for (soluble) endoglin in paracrine signaling, without directly affecting proliferation or migration in an autocrine manner.

01 Jan 2023·Molecular therapy : the journal of the American Society of Gene Therapy

Antagonizing CD105 and androgen receptor to target stromal-epithelial interactions for clinical benefit

Article

Author: Zhang, Le ; Posadas, Edwin M ; Kim, Minhyung ; You, Sungyong ; Billet, Sandrine ; Duong, Frank ; Madhav, Anisha ; Placencio-Hickok, Veronica R ; Smith, Bethany N ; Angara, Bryan ; Scher, Kevin ; Bhowmick, Neil A ; Oppenheim, Amy ; Moldawer, Nancy ; Tighiouart, Mourad ; Mishra, Rajeev

Androgen receptor signaling inhibitors (ARSIs) are standard of care for advanced prostate cancer (PCa) patients. Eventual resistance to ARSIs can include the expression of androgen receptor (AR) splice variant, AR-V7, expression as a recognized means of ligand-independent androgen signaling. We demonstrated that interleukin (IL)-6-mediated AR-V7 expression requires bone morphogenic protein (BMP) and CD105 receptor activity in both PCa and associated fibroblasts. Chromatin immunoprecipitation supported CD105-dependent ID1- and E2F-mediated expression of RBM38. Further, RNA immune precipitation demonstrated RBM38 binds the AR-cryptic exon 3 to enable AR-V7 generation. The forced expression of AR-V7 by primary prostatic fibroblasts diminished PCa sensitivity to ARSI. Conversely, downregulation of AR-V7 expression in cancer epithelia and associated fibroblasts was achieved by a CD105-neutralizing antibody, carotuximab. These compelling pre-clinical findings initiated an interventional study in PCa patients developing ARSI resistance. The combination of carotuximab and ARSI (i.e., enzalutamide or abiraterone) provided disease stabilization in four of nine assessable ARSI-refractory patients. Circulating tumor cell evaluation showed AR-V7 downregulation in the responsive subjects on combination treatment and revealed a three-gene panel that was predictive of response. The systemic antagonism of BMP/CD105 signaling can support ARSI re-sensitization in pre-clinical models and subjects that have otherwise developed resistance due to AR-V7 expression.

News (Medical) associated with Carotuximab

16 Dec 2024

·www.accesswire.com

Kairos Pharma to Participate in The Microcap Conference in January 2025

LOS ANGELES, CA / ACCESSWIRE / December 16, 2024 / Kairos Pharma, (NYSE American:KAPA) a clinical stage biotechnology company is pleased to announce its participation in The Microcap Conference 2025, the premier event for growth-focused companies and investors. The conference will take place January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ.Kairos Pharma's management team will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company's recent developments, growth strategy, and investment opportunities.About The Microcap Conference 2025The Microcap Conference is the largest independent microcap event in the U.S., bringing together top-tier investors and executives from microcap companies. The event offers a platform for companies to showcase their value propositions through presentations, one-on-one meetings, and networking opportunities.The 2025 event will feature:Keynote Speakers: Renowned industry figures, including Jon Ledecky, Co-Owner of the New York Islanders, who will engage in a fireside chat with CNBC's Bob Pisani; plus Tom Gardner, CEO of Motley Fool, who will share insights on investing, market trends, and entrepreneurial success.Expert Panels and Presentations: Financial commentators Ron Insana (CNBC) and Charlie Gasparino (FOX Business) will cover critical topics for the US equity markets, from capital formation to regulatory updates and market trends.Entertainment Headliner: A special performance by Tom Papa, celebrated comedian and host of Netflix specials, ensuring a memorable evening for attendees.Hosted by DealFlow Events, The Microcap Conference is renowned for its blend of high-quality content, engaging networking, and exceptional entertainment. For more information, visit https://themicrocapconference.com.About Kairos Pharma Ltd.Based in Los Angeles, California, Kairos Pharma Ltd. (NYSE American:KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105-a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer aimed at addressing significant unmet medical needs. For more information, visit kairospharma.com.Contact:CORE IRLouie Toma[email protected]SOURCE: Kairos Pharma Ltd.

Phase 2Phase 1

03 Dec 2024

·www.businesswire.com

Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial

LOS ANGELES--( BUSINESS WIRE )-- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, today announces the addition of City of Hope Cancer Center in Duarte, California to the Phase 2 clinical trial for ENV105 for castrate-resistant prostate cancer patients. City of Hope Cancer Center is the first of several planned new centers to be added in the coming weeks to support the Company’s randomized trial for patients receiving either apalutamide or apalutamide+ENV105 combination therapy. The additional centers allow Kairos Pharma to test ENV105 in a broader patient population to identify blood markers that could help select patients expected to benefit most from ENV105 treatment. The trial is supported by Kairos Pharma Ltd. and a grant from the National Cancer Institute (NCI). Kairos Pharma Chief Scientific Officer Dr. Neil Bhowmick said, “The preclinical findings suggest that ENV105 blocks a central mechanism of hormone therapy resistance. We are encouraged that we have multiple peer-reviewed articles in addition to receiving an NCI grant that supports the solid science behind this trial. We are fortunate to be working with the talented and experienced oncologists at City of Hope, who will be key participants in a trial that may provide patients with a new alternative to the current standard of care.” Kairos CEO Dr. John Yu added, “This is an important milestone in our mission to develop first-in-class approaches to address the inevitable resistance that develops in prostate cancer patients receiving hormone therapy, as it provides additional validation for the science behind ENV105. City of Hope is a first-class research institution, and we look forward to our continued collaboration with them.” About Kairos Pharma Ltd. Based in Los Angeles, California, Kairos Pharma Ltd. ( NYSE American: KAPA ) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105—a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer aimed at addressing significant unmet medical needs. For more information, visit kairospharma.com . Forward-Looking Statements This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential” or “hopes” or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including: our expectations regarding the success and/or completion of our Phase 1 and Phase 2 clinical trials; our success in completing newly initiated clinical trials, commence new trials, and obtain regulatory approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including those described in Kairos Pharma’s prospectus and other filings made with the SEC. We are not obligated to publicly update or revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information or future events or developments, except as required by U.S. federal securities laws.

Phase 2Phase 1

19 Nov 2024

·www.globenewswire.com

Kairos Pharma Approved to Dual List on Upstream

Trading to begin November 26, 2024 under ‘KAPA’LOS ANGELES, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd. (KAPA) today announced its approval to dual list its shares on Upstream, a MERJ Exchange market and global securities trading app. Trading will be available on Upstream November 26 at 10:00am ET under the ticker symbol ‘KAPA.’ The dual listing on Upstream is designed to provide Kairos Pharma the opportunity to access a global investor base outside the U.S., unlocking liquidity and enhancing price discovery while globalizing the opportunity to invest in Kairos Pharma. Investors outside the U.S. can get ready to trade by downloading Upstream from their preferred app store at https://upstream.exchange/, creating an account by tapping Sign Up, and completing a simple KYC identity verification by tapping the profile icon on the home screen and tapping KYC. Details on the Kairos Pharma listing and deposit and trading instructions can be found at kairospharma.com. Traders on Upstream’s smart contract-powered platform will experience real-time trading and settlement, and a transparent orderbook which does not permit common market manipulations. Dr. John Yu, CEO of Kairos Pharma, commented, “Building shareholder value is an ongoing goal of Kairos. We believe a dual listing on Upstream’s next generation market greatly supports this goal as we continue to expand our lead drug ENV105 to several widespread cancers and to advance our therapeutics through clinical testing and commercialization.” About Kairos Pharma Ltd. Based in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105—a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate resistant prostate cancer and a Phase 1 trial for lung cancer, addressing significant unmet medical needs. For more information, visit kairospharma.com. About Upstream Upstream, a MERJ Exchange market (https://merj.exchange/), is a global securities trading app. Powered by Horizon's proprietary, transparency-first, matching engine, Upstream allows investors outside of the U.S. to trade securities using just an app. For more information, please visit https://upstream.exchange/. Upstream is currently accepting applications to dual list at https://upstream.exchange/getlisted. Disclaimers U.S. persons may not deposit, buy, or sell securities on Upstream. This communication does not constitute an offer to sell securities or the solicitation of an offer to buy securities in any jurisdiction where such offer or solicitation is not permitted. Upstream is a MERJ Exchange market. MERJ Exchange is a licensed Securities Exchange, an affiliate of the World Federation of Exchanges, a National Numbering Agency, and a member of ANNA. MERJ is regulated in the Seychelles by the Financial Services Authority, https://fsaseychelles.sc/, an associate member of the International Association of Securities Commissions (IOSCO). MERJ supports global issuers of traditional and digital securities through the entire asset life cycle from issuance to trading, clearing, settlement, and registry. It operates a fair and transparent marketplace in line with international best practices and principles of operations of financial markets. Upstream does not endorse or recommend any public or private securities bought or sold on its app. Upstream does not offer investment advice or recommendations of any kind. All services offered by Upstream are intended for self-directed clients who make their own investment decisions without aid or assistance from Upstream. All customers are subject to the rules and regulations of their jurisdiction. By accessing the site or app, you agree to be bound by its terms of use and privacy policy. Company and security listings on Upstream are only suitable for investors who are familiar with and willing to accept the high risk associated with speculative investments, often in early and development-stage companies. U.S. persons may not deposit, buy, or sell securities on Upstream. There can be no assurance the valuation of any particular company's securities is accurate or in agreement with the market or industry comparative valuations. Investors must be able to afford market volatility and afford the loss of their investment. Companies listed on Upstream are subject to significant ongoing corporate obligations including, but not limited to disclosure, filings, and notification requirements, as well as compliance with applicable quantitative and qualitative listing standards. Forward-Looking Statements This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential” or “hopes” or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including: our expectations regarding the success and/or completion of our Phase 1 and Phase 2 clinical trials; our success in completing newly initiated clinical trials, commence new trials, and obtain regulatory approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including those described in Kairos Pharma’s prospectus and other filings made with the SEC. We are not obligated to publicly update or revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information or future events or developments, except as required by U.S. federal securities laws. Contact: CORE IRLouie Tomainvestors@kairospharma.com

Phase 2Phase 1

100 Deals associated with Carotuximab

External Link

KEGG	Wiki	ATC	Drug Bank
D11260	Carotuximab	-	DB06322

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hemangiosarcoma	Phase 3	US	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hemangiosarcoma	Phase 3	AT	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hemangiosarcoma	Phase 3	FR	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hemangiosarcoma	Phase 3	DE	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hemangiosarcoma	Phase 3	IT	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hemangiosarcoma	Phase 3	PL	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hemangiosarcoma	Phase 3	ES	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hemangiosarcoma	Phase 3	GB	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Metastatic castration-resistant prostate cancer	Phase 2	US	Cedars-Sinai Medical Center	05 Mar 2018
Prostatic Cancer	Phase 2	US	Cedars-Sinai Medical Center	05 Mar 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02520063 (CTgov)	Phase 1/2	Locally advanced breast cancer \| Hormone receptor positive HER2 negative breast cancer	15	Letrozole+everolimus+TRC105 (Phase I Cohort 1)	lqeevnjoyc(zrniuxitxy) = pblgbmlhhj bytjqwagaw (dvpwzmqdda, jnhpaxjywv - ntslbwxhzr) View more	-	21 Aug 2023
				Letrozole+everolimus+TRC105 (Phase I Cohort 2)	lqeevnjoyc(zrniuxitxy) = ytazrsmqcf bytjqwagaw (dvpwzmqdda, qepiigrkbc - tdwqwspesw) View more
NCT02979899 (TAPPAS, Pubmed) Manual	Phase 3	Hemangiosarcoma	114	TRC105+Pazopanib	kivdugvmbz(dzmhoueczk) = zcshnvqaqe pvmqaclyhd (alygotgvkl, 2.8 - 8.3)	Positive	31 Mar 2022
				Pazopanib	kivdugvmbz(dzmhoueczk) = ylaekjfabr pvmqaclyhd (alygotgvkl, 2.9 - NR)
NCT03211234 (CTgov)	Phase 2	Wet age-related macular degeneration	76	Lucentis (Sham)	mymmkzxolg(slnogrgccc) = xmkhgotdqt ydgnodqzfd (ezknwjpads, spdhifvxiu - wizcbfgkom) View more	-	13 Jul 2021
				DE-122+Lucentis (2.0 mg DE-122)	mymmkzxolg(slnogrgccc) = bkmqwettbe ydgnodqzfd (ezknwjpads, rhyxraxjur - zijteckqqa) View more
NCT03418324 (CTgov)	Phase 2	Prostatic Cancer \| Metastatic castration-resistant prostate cancer	11	Abiraterone+TRC105 (Arm A: TRC105 + Abiraterone)	spjqxzpkht(qzdztufvkm) = zhzgppwnjt icoijoqkrr (emukwmmnsz, blbnhdfdxq - epkmjsbtvq) View more	-	30 Dec 2020
				Enzalutamide+TRC105 (Arm E: TRC105 + Enzalutamide)	spjqxzpkht(qzdztufvkm) = opwvcogxri icoijoqkrr (emukwmmnsz, arrqjswrtc - sapbinmpqk) View more
NCT01806064 (TRAXAR, CTgov)	Phase 1/2	Metastatic Renal Cell Carcinoma	173	Axitinib+TRC105 (P1b: 8 mg/kg TRC105 Wkly + 5 mg Axitinib BID)	ddfzfyethq(jurxndgjew) = kzsbhcnjdn ufngkvxcpv (wzcuohissu, pzhggnkiox - axqhnmoggv) View more	-	19 Oct 2020
				Axitinib+TRC105 (P1b: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID)	ddfzfyethq(jurxndgjew) = nyjzjvgved ufngkvxcpv (wzcuohissu, rqqcsxgkwc - herzksjtxg) View more
NCT03181308 (CTgov)	Phase 1	metastatic non-small cell lung cancer	11	Nivolumab+TRC105 (8 mg/kg TRC105 + Nivolumab)	qktjgqukmv(mtcpsddnum) = qyhimqmjoh iybazurgnc (vqgzscnefo, aukzbxauhx - fzyxqlgaxt) View more	-	24 Jun 2020
				Nivolumab+TRC105 (10 mg/kg TRC105 + Nivolumab)	qktjgqukmv(mtcpsddnum) = osyjigqada iybazurgnc (vqgzscnefo, mteuhpcymz - tmwnhvquaj) View more
NCT02979899 (TAPPAS, CTgov)	Phase 3	Hemangiosarcoma	128	Votrient	aukdzdtuun(dhbgfyikyd) = zyoysgspra rrojlncxzs (kxjqijkook, lloyqqqhng - nvgofntvmd) View more	-	12 May 2020
NCT01975519 (CTgov)	Phase 1/2	Sarcoma \| Locally Advanced Soft Tissue Sarcoma \| Hemangiosarcoma	111	TRC105+Pazopanib (TRC105 Plus Pazopanib)	nqbszmwjen(unrtrwliep) = exmluaktzx dffleomvod (fknpwllipc, yomihevrvp - lynffrvxbx) View more	-	12 May 2020
				TRC105+Pazopanib (8 mg/kg TRC105 + Pazopanib)	roowxvnlyd(cifqnnkxkh) = nsszqsjnqt ckogxotoda (pwejznjrxk, mkultgldes - mlkugvpvlr) View more
NCT02555306 (PAVE, CTgov)	Phase 1/2	Age Related Macular Degeneration	12	DE-122 (0.5 mg of DE-122)	adfgsioaxb(mnfwllpczd) = hdsmnldrla ggbikbwezq (vbxowztjyy, xqqnancvre - kztldmgpuw) View more	-	14 Jan 2020
				DE-122 (1.0 mg of DE-122)	adfgsioaxb(mnfwllpczd) = jfslklojgf ggbikbwezq (vbxowztjyy, davgdqmbje - jkctbxkwii) View more
NCT01806064 (TRAXAR, ESMO 12019 \| ESMO 22019) Manual	Phase 2	Renal Cell Carcinoma	150	Axitinib+TRC105	fmldprvopd(bpcbssyjnz) = ldjoajsjuv uqpjslocmb (msykftrghc, 5.6 - 13.1) View more	Negative	29 Sep 2019
				Axitinib	fmldprvopd(bpcbssyjnz) = tgankuqevs uqpjslocmb (msykftrghc, 5.8 - NE) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis